Abstract 229P
Background
Fatigue is a common adverse effect suffered by prostate cancer patients receiving androgen deprivation therapy (ADT). A growing body of evidence has proposed exercise as a treatment to relieve and prevent the adverse effects of ADT. Recently, high-quality randomized controlled trials (RCTs) of supervised exercise have been conducted to get more assessment. However, the pooled estimate for the effect of supervised exercise on fatigue has not been established yet. This study aims to determine the pooled effect of supervised exercise on fatigue in prostate cancer patients receiving ADT.
Methods
A literature search was conducted from PubMed, Clinicaltrial, and Cochrane Library, published up to January 2020 following the PRISMA guideline. We screened RCTs with our inclusion criteria and assessed the quality using the tools provided by Cochrane. The primary outcome analyzed in this study was fatigue measured as Standardized Mean Difference (SMD) with 95% Confidence Intervals (CIs). Heterogeneity was assessed using the I2 test. Subgroup analysis was conducted to determine the difference in exercise duration (<12 weeks and >12 weeks), modality (aerobic, resistance, and combination), and the onset of ADT (initiation and long-term). All analysis was performed using STATA 16.
Results
A total of 7 RCTs comprising 455 patients reported the fatigue using the FACIT-Fatigue, EORTC QLQ-C30, and Schwartz Cancer Fatigue Scale. The included studies presented a low risk of bias. Supervised exercise showed an overall reduction on fatigue (SMD = 0.25, 95%CI 0.07-0.44, p = 0.01, I2 = 0%). The subgroup test results showed no significant difference between exercise duration (p = 0.4), modality (p = 0.67), and onset of ADT (p = 0.57). The Egger’s test results showed no indication of publication bias (p = 0.64).
Conclusions
Supervised exercise reduces fatigue in prostate cancer patients receiving ADT. The available data show that there is no difference between exercise duration and modality. Furthermore, our findings highlight the benefits of supervised exercise in the initiation of ADT for preventing toxicities as well as relieving adverse effects in long-term ADT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
424P - Hippocampus sparing in volumetric modulated arc therapy (VMAT) for brain tumour radiotherapy treatment
Presenter: Eva Yi Wah Cheung
Session: e-Poster Display Session
425P - The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents
Presenter: Chun Loo Gan
Session: e-Poster Display Session
426P - A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
Presenter: Marcia S. Brose
Session: e-Poster Display Session
427P - On the clinical implications of systemic and local immune responses in human angiosarcoma
Presenter: Jason Yongsheng Chan
Session: e-Poster Display Session
428P - Prognostic value of clinico-pathological characteristics and peripheral monocyte counts in localised extra-meningeal solitary fibrous tumours treated with surgical resection
Presenter: Ryan Lim
Session: e-Poster Display Session
429P - Demographics, pattern of care, and outcome analysis of malignant melanoma cases from a tertiary care centre in India
Presenter: Anshul Agarwal
Session: e-Poster Display Session
430P - Teenagers and young adult cancers in rural central India: Access to age-appropriate care
Presenter: Runu Sharma
Session: e-Poster Display Session
431P - Quantitative study of two critical lncRNAs in patients with glioma tumours
Presenter: Kamal Mohammadian
Session: e-Poster Display Session
432P - Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma
Presenter: Mustafa Gürbüz
Session: e-Poster Display Session
433P - Association between aspirin and cancer risk: A Mendelian randomization analysis
Presenter: Yu Jiang
Session: e-Poster Display Session